$0.000001 PHASQ stock on PNK 13 Jan 2026: PhaseBio Pharmaceuticals outlook
PHASQ stock opened market hours on 13 Jan 2026 at $0.000001, down -99.00% from the previous close of $0.000100 on the PNK exchange in the United States. Trading volume was 2,500.00 shares versus a 50‑day average of 22,310.00, positioning PhaseBio Pharmaceuticals among today’s top losers. The move reflects lingering Chapter 11 restructuring risk, pipeline uncertainty around bentracimab (PB2452), and thin liquidity. We examine valuation, key ratios, Meyka AI grading, and price scenarios to help investors understand the downside exposure and any potential catalysts.
Market snapshot for PHASQ stock
PHASQ stock last traded at $0.000001 on PNK with a day low and high of $0.000001 and a year high of $0.03990. Average price metrics show a 50‑day average of $0.000236 and a 200‑day average of $0.000666, indicating a long downtrend. Volume of 2,500.00 versus avg volume 22,310.00 signals low liquidity and heightened bid‑ask risk. For recent media context see Markets Insider coverage source.
Why PHASQ stock moved into top losers territory
The primary driver for PHASQ stock weakness is continued uncertainty from the company’s 2022 Chapter 11 filing and thin trading that amplifies down moves. PhaseBio’s lead asset bentracimab (PB2452) remains in clinical development but faces commercial and co‑development complexity with partners. Combined market sentiment and the stock’s extremely low market cap have produced a -99.00% day move and multi‑period declines reflected in 1‑month and 3‑month declines near -99.00% to -99.50%.
Financials and valuation metrics for PHASQ stock
PhaseBio reports trailing EPS of -2.14 and a negative P/E structure reflecting ongoing losses; key metrics show a cash per share of $1.421879 and book value per share of -3.164667, indicating capital shortfall versus liabilities. Price averages are $0.000236 (50‑day) and $0.000666 (200‑day). Operating cash flow per share is -1.612914, free cash flow per share -1.704044, and current ratio 1.75, underlining funding risk for continued development.
Meyka AI rates PHASQ with a score out of 100
Meyka AI rates PHASQ with a score out of 100: 59.07 (C+) — HOLD. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. The C+ reflects short‑term downside risk offset by remaining pipeline value. These grades are not guaranteed and are informational, not financial advice.
Analyst price targets and scenario analysis for PHASQ stock
We outline three scenarios: a conservative recovery target $0.000100 (flat to slight recovery), a base case $0.00100 (modest pipeline progress), and an optimistic turnaround $0.01000 if bentracimab clears Phase III and balance sheet improves. Implied moves versus current $0.000001 are +9,900.00%, +99,900.00%, and +999,900.00% respectively; all scenarios depend on financing and trial outcomes, so timing is uncertain.
Risks and potential catalysts for PHASQ stock
Key risks: restructuring outcomes from the Chapter 11 process, continued dilution from financing, trial setbacks for PB2452, and negligible liquidity on PNK. Catalysts include positive Phase III data, successful co‑development milestones, or strategic asset sales. Sector context: biotechnology index moves and healthcare investor risk appetite will influence any recovery prospects.
Final Thoughts
PHASQ stock is trading at $0.000001 on PNK on 13 Jan 2026 after a severe multi‑period decline and remains a highly speculative holding. Balance sheet metrics such as cash per share $1.421879 provide a limited runway but operating cash burn and past Chapter 11 activity keep downside risk elevated. Meyka AI’s forecast model projects $0.00 over the next 12 months, implying a theoretical -100.00% move versus the current price; forecasts are model‑based projections and not guarantees. Investors should weigh severe liquidity risk and binary clinical outcomes before exposure. For active traders, watch volume spikes, news on PB2452, and any restructuring updates. Meyka AI, an AI‑powered market analysis platform, flags PHASQ as high risk with potential high reward only if trial and financing dynamics change materially.
FAQs
What caused the sharp drop in PHASQ stock today?
PHASQ stock fell due to thin liquidity, continued Chapter 11 restructuring uncertainty, low average volume, and ongoing pipeline risk for bentracimab (PB2452), which together amplified negative price action.
Does PHASQ stock have any realistic price targets?
Price scenarios range from a conservative $0.000100 to a base $0.00100 and optimistic $0.01000, driven by financing and trial success; these are scenario estimates, not guarantees.
How does Meyka AI grade PHASQ stock affect the outlook?
Meyka AI gives PHASQ a 59.07 (C+) HOLD grade based on benchmark and sector comparisons, financial metrics, and analyst inputs; the grade is informational and not investment advice.
What are the main risks if I consider PHASQ stock?
Main risks include Chapter 11 outcomes, dilution from capital raises, clinical trial failure for PB2452, and extremely low liquidity that can magnify losses and widen spreads.
Disclaimer:
Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.
